Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-03-20
1993-12-21
Daus, Donald G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544262, 514 17, 514 18, 514 19, 530330, 530331, A61K 31495
Patent
active
052721515
ABSTRACT:
The present invention concerns aminoacyl and oligopeptidyl derivatives of allopurinol (1,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one) of general formula (I), and related salts with ##STR1## pharmacologically-acceptable cations, in which n is an integer between 2 and 6, preferably 5, Y is H or CO--A, in which A is a racemic or chiral amino acid, dipeptide, tripeptide, tetrapeptide, or pentapeptide chosen, respectively, from the groups consisting of:
REFERENCES:
patent: 3165520 (1965-01-01), Schmidt
patent: 4567182 (1986-01-01), Ferraris
patent: 4602089 (1986-07-01), Simon
patent: 4663326 (1987-05-01), Hamilton
patent: 4694006 (1987-09-01), Bundgaard et al.
Chem. Abstr. vol. 104 Entry 19600h (1986), Abstr. WO85-00368.
Chem. Abstr. vol. 112 Entry 36465a (1990), Abstr WO89-05818.
Chem. Abstr vol. 99 Entry 122919w (1983), Abstr EP 77460.
Beauchamp et al., J. Med. Chem. vol. 28 pp. 982-987 (1985).
Kha-Vang-Thaug et al. Chem. Abstr vol. 74 Entry 107635r (1971).
Hans Bundgaard et al, "Allopurinol Prodrugs. IV Improved Rectal and Parenteral Delivery of Allopurinol Using the Prodrug Approach as Evaluated in Rabbits," International Journal of Pharmaceutics, vol. 27, (1985), pp. 71-80.
Kha Vang Thang et al, "Inhibition De La Xanthine-Oxydase Par l'Allopurinol (1 H-5 H Dihydro-4,5 Pyrazolo [3,4-D] Pyrimidinone-4) (Etude Du Processus D'Oxydation et de L'Effet de l'Aminomethylation)," C.R. Acad. SC. Paris, vol. 272, Jan. 25, 1971, pp. 639-642.
Roland K. Robins et al, "Purine Analog Inhibitors of Xanthine Oxidase--Structure Activity Relationship and Proposed Binding of the Molybdenum Cofactor," J. Heterocyclic Chem., vol. 22, (1985), pp. 601-634.
Derwent Abstract of WO89-05818 (1989).
B. R. Baker et al, "Irreversible Enzyme Inhibitors. CXXVI. Hydrocarbon Interaction with Xanthine Oxidase by Phenyl Substituents on Purines and Pyrazolo[3,4-D]Pyrimidines," J. Med. Chem., vol. 11, (1968), pp. 661-666.
R. Stradi et al, "Synthetic Biological Response Modifiers; Part 1. Synthesis and Immunomodulatory Properties of Some N.sup.2 -(.omega.-(Hypoxanthin-9-Yl)Alkoxycarbonyl)-L-Arginines," Il Farmaco, vol. 45, (1990), pp. 39-47.
Luis H. Toledo-Pere Yra et al, "A Study of the Immunosuppressive Effect of Allopurinol," Immunological Communications, vol. 9(1), (1980), pp. 7-11.
Foresta Piero
Marzi Mauro
Minetti Patrizia
Tinti Maria O.
Daus Donald G.
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Aminoacyl and oligopeptidyl derivatives of allopurinol exhibitin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoacyl and oligopeptidyl derivatives of allopurinol exhibitin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoacyl and oligopeptidyl derivatives of allopurinol exhibitin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-309221